You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Looking Ahead in Complement-Mediated Kidney Diseases: What Clinical Questions Do Current Trials Aim to Answer

  • Authors: Vladimir Tesar, MD, PhD, MBA, FERA, FASN; Smeeta Sinha, MbChB, FRCP, PhD
  • CME / ABIM MOC Released: 5/30/2023
  • Valid for credit through: 5/30/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US pediatricians, nephrologists, and pathologists.

The goal of this activity is for learners to be better able to provide a comprehensive overview of the current complement inhibitors that are being investigated in clinical trials for kidney diseases.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current unmet needs in the management of patients with complement-mediated kidney disease
    • Emerging targeted therapies for complement-mediated kidney diseases


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Moderator

  • Vladimir Tesar, MD, PhD, MBA, FERA, FASN

    Professor of Internal Medicine
    General University Hospital
    Charles University
    Prague, Czech Republic

    Disclosures

    Vladimir Tesar, MD, PhD, MBA, FERA, FASN, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Calliditas Therapeutics; Novartis; Omeros Corporation; Otsuka Pharmaceutical Co., Ltd.; Travere Therapeutics

Faculty

  • Smeeta Sinha, MBChB, FRCP, PhD

    Professor of Nephrology
    Salford Royal Hospital
    Northern Care Alliance NHS Foundation Trust
    Salford, United Kingdom

    Disclosures

    Smeeta Sinha, MBChB, FRCP, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Inozyme Pharma Inc.; Sanifit
    Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; CSL Vifor; GlaxoSmithKline; Novartis; Sanofi-Genzyme
    Research funding from: Amgen Inc.; AstraZeneca Pharmaceuticals LP; CSL Vifor

Editor

  • Rita Moreira Da Silva, PhD, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Rita Moreira Da Silva, PhD, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Looking Ahead in Complement-Mediated Kidney Diseases: What Clinical Questions Do Current Trials Aim to Answer

Authors: Vladimir Tesar, MD, PhD, MBA, FERA, FASN; Smeeta Sinha, MbChB, FRCP, PhDFaculty and Disclosures

CME / ABIM MOC Released: 5/30/2023

Valid for credit through: 5/30/2024, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to provide a comprehensive overview of the current complement inhibitors that are being investigated in clinical trials for kidney diseases.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print